SCHEMBL24499265

SCHEMBL24499265

CC(C)c1cc(F)ccc1OC1CCOCC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 1/20 0.48
PDE4D Q08499 9/20 0.42
PDE4A P27815 5/20 0.42
PDE4B Q07343 5/20 0.42
PDE4C Q08493 5/20 0.42
KAT2B Q92831 1/20 0.42
BAZ2B Q9UIF8 1/20 0.42
EGFR P00533 1/20 0.40
SOS1 Q07889 1/20 0.40
PSEN1 P49768 1/20 0.39
PSEN2 P49810 1/20 0.39
APH1B Q8WW43 1/20 0.39
NCSTN Q92542 1/20 0.39
APH1A Q96BI3 1/20 0.39
PSENEN Q9NZ42 1/20 0.39
GPR6 P46095 1/20 0.39
NTRK1 P04629 1/20 0.38
VEGFA P15692 1/20 0.38
PDE9A O76083 1/20 0.37
JAK2 O60674 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24499266 0.92 PDE4D (0.46) SYKPDE4DPDE4APDE4BPDE4C
SCHEMBL26505523 0.89 EPHX2 (0.40) PDE4AGPR6
SCHEMBL24499180 0.86 PDE4A (0.42) PDE4DPDE4APDE4BPDE4CGPR6
SCHEMBL798745 0.81 KAT2B (0.52) SYKPDE4DPDE4APDE4BPDE4C
SCHEMBL18559551 0.81 HTR2C (0.46) GPR6
SCHEMBL22040926 0.79 KAT2B (0.45) SYKPDE4DPDE4APDE4BPDE4C
SCHEMBL24780615 0.77 SYK (0.51) SYKPDE4DPDE4APDE4BPDE4C
SCHEMBL26505568 0.77 FFAR4 (0.36) SYKPDE4DPDE4APDE4BPDE4C
SCHEMBL24780614 0.76 SYK (0.42) SYKPDE4DPDE4APDE4BPDE4C
SCHEMBL1937164 0.74 SYK (0.44) SYKPDE4DPDE4APDE4BPDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230139111-A1 DIHYDRONAPHTHYRIDINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) 2023-05-04 US disclosed
US-20230139111-A1 DIHYDRONAPHTHYRIDINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) 2023-05-04 US disclosed
US-20220177462-A1 SUBSTITUTED HETEROCYCLIC AMIDE COMPOUND AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) 2022-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230139111-A1 DIHYDRONAPHTHYRIDINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF RIPK1, RIPK4, RIPK3 SYK 2352/4885PDE4D 1339/4885PDE4A 1076/4885
US-20220177462-A1 SUBSTITUTED HETEROCYCLIC AMIDE COMPOUND AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF RIPK1, RIPK4, RIPK3 SYK 1433/4885PDE4D 2519/4885PDE4A 2139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.